



# UNIVERSITÀ DI PARMA

## ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis

This is the peer reviewed version of the following article:

*Original*

Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis / Micek, A.; Godos, J.; Del Rio, D.; Galvano, F.; Grosso, G.. - In: MOLECULAR NUTRITION & FOOD RESEARCH. - ISSN 1613-4125. - 65:6(2021), p. 2001019.e2001019. [10.1002/mnfr.202001019]

*Availability:*

This version is available at: 11381/2902096 since: 2021-10-29T15:40:37Z

*Publisher:*

John Wiley and Sons Inc

*Published*

DOI:10.1002/mnfr.202001019

*Terms of use:*

Anyone can freely access the full text of works made available as "Open Access". Works made available

*Publisher copyright*

note finali coverpage

(Article begins on next page)



### **Dietary flavonoids and cardiovascular disease: a comprehensive dose-response meta-analysis**

Journal:	<i>Molecular Nutrition and Food Research</i>
Manuscript ID	mnfr.202001019.R2
Wiley - Manuscript type:	Research Article
Date Submitted by the Author:	n/a
Complete List of Authors:	Micek, Agnieszka Godos, Justyna; Oasi Research Institute - IRCCS, Del Rio, Daniele; University of Parma, Food Science Galvano, Fabio; University of Catania, Department of Biological Chemistry, Medical Chemistry and Molecular Biology Grosso, Giuseppe; Integrated Cancer Registry of Catania-Messina- Siracusa-Enna,
Keywords:	cardiovascular diseases, cohort, flavonoid, meta-analysis, stroke

SCHOLARONE™  
Manuscripts

1  
2  
3 **Dietary flavonoids and cardiovascular disease: a comprehensive dose-response meta-**  
4 **analysis**  
5  
6  
7  
8  
9

10 Agnieszka Micek<sup>1</sup>, Justyna Godos<sup>2</sup>, Daniele Del Rio<sup>3,4</sup>, Fabio Galvano<sup>2</sup>, Giuseppe Grosso<sup>2</sup>  
11  
12  
13

14 <sup>1</sup> Department of Nursing Management and Epidemiology Nursing, Faculty of Health  
15 Sciences, Jagiellonian University Medical College, Kraków, Poland;  
16

17 <sup>2</sup> Department of Biomedical and Biotechnological Sciences, University of Catania, Catania,  
18 Italy;  
19

20 <sup>3</sup> School of Advanced Studies on Food and Nutrition, University of Parma, Parma, Italy;  
21

22 <sup>4</sup> Department of Veterinary Science, University of Parma, Parma, Italy.  
23  
24  
25  
26  
27  
28  
29

30 Correspondence: Agnieszka Micek, PhD. Department of Nursing Management and  
31 Epidemiology Nursing, Faculty of Health Sciences, Jagiellonian University Medical College,  
32 Kraków, Poland; email: [agnieszka.micek@uj.edu.pl](mailto:agnieszka.micek@uj.edu.pl).  
33  
34  
35  
36  
37  
38  
39

40 **Abbreviations:**

41  
42 CHD coronary heart disease  
43

44 CIs confidence intervals  
45

46 CVD cardiovascular disease  
47

48 DALYs disability-adjusted life-years  
49

50 FFQ food frequency questionnaire  
51

52 FMD flow-mediated dilation  
53

54 HRs hazard ratios  
55

56 MOOSE meta-analysis of observational studies in epidemiology  
57  
58  
59  
60

1  
2  
3 NF- $\kappa$ B nuclear factor kappa-light-chain-enhancer of activated B cells  
4

5 NO nitric oxide  
6

7  
8 NOS newcastle-ottawa quality assessment scale  
9

10 Nrf2 nuclear factor erythroid 2-related factor 2  
11

12 RCTs randomized controlled trials  
13

14 RRs relative risks  
15

16  
17 TNF-  $\alpha$  tumor necrosis factor  
18  
19

20  
21 **Keywords:** cardiovascular diseases; cohort; flavonoid; meta-analysis; stroke.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

**Scope** Dietary flavonoids have shown potential in the prevention of non-communicable diseases. The aim of the present study was to conduct a dose-response meta-analysis on the association between dietary intake of total, subclasses and individual flavonoids and risk of cardiovascular disease (CVD). **Methods and results** Electronic databases were searched. A total of 39 prospective cohort studies were included, comprising 1,501,645 individuals and a total of 33,637 cases of CVD, 23,664 of coronary heart disease (CHD), and 11,860 of stroke. Increasing dietary intake of total flavonoids was linearly associated with lower risk of CVD. Among the main classes of flavonoids, increasing intake of anthocyanins and flavan-3-ols was inversely associated with risk of CVD, while flavonols and flavones with CHD. Only increasing flavanones showed a linear inverse association with stroke risk. Catechins showed a favourable effect toward all cardiovascular outcomes. Among individual compounds, intake of quercetin and kaempferol was linearly associated with lower risk of CHD and CVD, respectively. However, higher intake of all the aforementioned compounds was associated, with a various extent, to lower risk of CVD when considering comparison of extreme categories of consumption. **Conclusion** The results of this study provide evidence of potential cardiovascular benefits of a flavonoid-rich diet.

## Introduction

In 2017, cardiovascular disease (CVD) has been estimated to have caused 17,8 million deaths worldwide.<sup>(1)</sup> Among the leading modifiable risk factors, dietary risks accounted for 10,9 million deaths and 255 million disability-adjusted life-years (DALYs) worldwide.<sup>(2)</sup>

Epidemiological research has globally demonstrated that dietary patterns rich in plant-based foods may play an important role in reducing the risk of CVD. Together with high consumption of fruit and vegetables,<sup>(3)</sup> other dietary components such as olive oil,<sup>(4)</sup> nuts,<sup>(5)</sup> whole-grains,<sup>(6)</sup> cocoa,<sup>(7)</sup> coffee<sup>(8)</sup> and tea<sup>(9)</sup> have been reported to exert beneficial effects toward CVD. Based on current evidence, public health experts advocate for healthier diets in order to achieve significant improvements in decreasing the global burden of CVDs.<sup>(10, 11)</sup>

Besides their content in vitamins and fiber, the aforementioned food groups are known for a relatively high content in polyphenols.<sup>(12)</sup> These compounds are bioactive molecules with diverse chemical structure, bioavailability, and biological activity, catabolised by the gut microbiome into smaller phenolic and aromatic acids.<sup>(12)</sup>

Dietary polyphenols have been shown to modulate multiple cell pathways, mainly through exerting anti-oxidant and anti-inflammatory properties, ultimately with potential positive effects toward human health. Previous comprehensive analyses of observational studies showed an inverse association between dietary flavonoid intake and mortality, including CVD related mortality,<sup>(13)</sup> risk of hypertension,<sup>(14)</sup> as well as cancer risk and survival.<sup>(15)</sup> Meta-analyses of intervention trials also showed the potentiality of specific flavonoids in positively affecting intermediary cardiovascular biomarkers, such as endothelial function, blood pressure, blood lipids,<sup>(16–18)</sup> and mediators of inflammation.<sup>(19)</sup> Recently, a systematic review pointed out possible implications of dietary flavonoids in cardiovascular health.<sup>(20)</sup> However, it is of paramount importance to assess and quantify the association between dietary flavonoid intake and risk of CVD among existing prospective cohort studies. A

1  
2  
3 previous meta-analysis evaluated the association for total flavonoid intake and risk of CVD  
4  
5 but did not take into account individual classes nor provided dose-response analysis.<sup>(21)</sup>  
6  
7 Moreover, distinction between type of CVD, such as coronary heart disease (CHD) and  
8  
9 stroke, have not been provided. Thus, the aim of the present study was to update and provide  
10  
11 a more comprehensive estimate of the association between dietary flavonoid intake,  
12  
13 individual subclasses and compounds and risk of CVDs in prospective cohort studies.  
14  
15  
16  
17

## 18 **Materials and methods**

19  
20 The reporting and methodology were conducted in accordance with the Meta-analysis of  
21  
22 Observational Studies in Epidemiology (MOOSE) guidelines (Supporting information Table  
23  
24 S1).  
25  
26  
27

### 28 *Study selection*

29  
30 To find all relevant reports we performed systematic search of Pubmed (<http://www.ncbi.nlm.nih.gov/pubmed/>) and EMBASE (<http://www.embase.com/>) databases. Only articles  
31  
32 published in English-language up to January 2020 were included. Search strategy comprised  
33  
34 clue terms defining the exposure, outcome and study type. The consecutive words and  
35  
36 phrases were combined with conjunction: (i) polyphenols OR flavonoids OR isoflavones OR  
37  
38 soy OR phenolic OR anthocyanins OR flavan-3-ols OR flavones OR flavonoids  
39  
40 OR flavanones OR catechins AND (ii) cardiovascular OR ischaemic heart disease OR  
41  
42 myocardial ischemia OR ischemic heart disease OR coronary artery disease OR coronary  
43  
44 heart disease OR stroke OR myocardial infarction OR cerebral infarction AND (iii) cohort  
45  
46 studies OR longitudinal studies OR prospective OR follow-up. The search terms and strategy  
47  
48 used for the study selection is shown in Supporting information Table S2. Studies were  
49  
50 included in the meta-analysis if met the following criteria: (i) having prospective design; (ii)  
51  
52 reporting dietary intake of total/classes/individual flavonoids as the exposure of interest; (iii)  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 reporting hazard ratios (HRs) or relative risks RRs (as equivalent measure) and the  
4  
5 corresponding 95% confidence intervals (CIs) for exposure divided to at least 3 categories,  
6  
7 (iv) being published in English language (v) reporting on the incidence of CVD or its subtype  
8  
9 as an outcome variable. We excluded: (i) non-original research and intervention trials  
10  
11 (commentaries, editorials or reviews); (ii) studies lacking sufficient statistics (method with  
12  
13 other measures of association than RRs or RRs given only for linear association); (iii) studies  
14  
15 with appropriate results given only for outcome other than CVD. Reference lists of selected  
16  
17 manuscripts were additionally examined to find any study not previously identified. If more  
18  
19 than one article characterising the same cohort was published, only the study describing the  
20  
21 entire cohort or with the longest follow-up was included. The selection process was  
22  
23 independently performed by two authors (J.G. and G.G.).  
24  
25  
26  
27  
28

#### 29 *Data extraction and study quality*

30  
31 Data was abstracted from selected studies using a standardized extraction form collecting the  
32  
33 following information: 1) first author name; 2) study cohort name; 3) countries where the  
34  
35 studies were conducted; 4) year of publication; 5) sex of participants; 6) number of  
36  
37 participants; 7) age of examined population at baseline; 8) follow-up period; 9) type of  
38  
39 dietary assessment instrument; 10) endpoints; 11) distributions of cases and person-years,  
40  
41 HRs/RRs, and 95% CIs across categories of exposure; 12) covariates used in adjustments.  
42  
43  
44

45 This process was independently performed by two authors (A.M. and G.G.) and discrepancies  
46  
47 were discussed and resolved by consensus.  
48  
49

50  
51 The quality of studies was assessed using the Newcastle-Ottawa Quality Assessment Scale  
52  
53 (NOS),<sup>(22)</sup> which consists of 3 domains: selection (4 points), comparability (2 points), and  
54  
55 outcome (3 points) for a total score of 9 points (higher score represents the higher quality).  
56  
57  
58  
59  
60



### *Statistical analysis*

The analyses were conducted for total flavonoid intake as well as for individual subclasses and compounds. When a study reported results separately for sex and for both in total, we included sex-specific estimations in analyses. As a measure of the association HRs or RRs with 95% CIs for all categories of exposure were extracted; both were deemed equivalently and further referred to as RRs. We collected only the most fully adjusted RRs from articles. The mean or median or midpoint of the range of intake in each category of flavonoid was assigned to the corresponding RR. To obtain summary statistics across the studies, the individual results were combined by random-effects meta-analyses. Heterogeneity was assessed by Cochran's Q test and I<sup>2</sup> statistic. The amount of total variation attributed to heterogeneity was categorised as no, small, moderate and high, according to following categories of I<sup>2</sup> values: <25%, 25–50%, 50–75%, and >75%, respectively. The level of significance of the Q test was set equal to 0.10. Dose-response relationship was modelled by restricted cubic splines with three knots at fixed percentiles of the flavonoid distribution (10%, 50%, and 90%).<sup>(23)</sup> Meta-analysis was conducted in two-stages. Firstly, study-specific coefficients were estimated on the basis of the results across the categories of flavonoid intake. The generalised least squares method was applied regarding the correlation within each set of retrieved RRs.<sup>(24, 25)</sup> Missing data on distribution of the number of participants/person-years or cases across categories of flavonoids were the prerequisite for using standard weighted least squares meta-regression.<sup>(24)</sup> By the multivariate extension of the method of moments between-study covariance matrices were assessed. Significant non-linearity was checked by testing whether the coefficient of the second spline was equal to zero. A sensitivity analysis by exclusion of one study at the time was conducted to assess the stability of the results and to detect the potential sources of heterogeneity. Subgroup analyses were performed for extreme categories of flavonoid consumption (highest versus lowest) by

grouping according to the following conditions: distinguishing between cardiovascular risk and mortality, sex, geographical area, follow-up time, sample size, quality of the study and adjustment for energy intake, diabetes status, BMI and dietary factors was performed.

Publication bias was evaluated by visual inspection of funnel plots for potential asymmetry.

All analyses were conducted using R software (Development Core Team, Vienna, Austria, version 3.6.1). Significance, except of Cochran's Q test, was set below the probability level of 0.05.

## Results

### *Study selection*

The article selection process is shown in Figure 1. Out of 46 studies evaluated in extenso, seven were excluded because of completely lack of RRs with 95% CIs or availability of estimations only for linear dose-response association (n = 3), or for soy food or specific classes of polyphenol not considered in the review (n = 4), leaving 39 articles for inclusion in the meta-analysis.<sup>(26–64)</sup>

### *Characteristics of the studies included*

The studies included 1,501,645 individuals and a total of 33,637 cases of CVD, 23,664 of coronary heart disease (CHD), and 11,860 of stroke. The countries where the studies were conducted were US (n = 12),<sup>(29, 32, 35, 38, 41, 43, 45–47, 55, 57, 58)</sup> Europe (n = 21),<sup>(26–28, 30, 31, 33, 34, 36, 37, 39, 40, 44, 49, 52, 53, 56, 60–64)</sup> Asia (n=5),<sup>(42, 48, 50, 54, 59)</sup> Australia (n=1).<sup>(51)</sup> Food frequency questionnaires (FFQs) were used as a tool to collect dietary information in 28 studies<sup>(29, 30, 32, 33, 35, 36, 38, 40–43, 45–52, 54, 55, 57–59, 61–64)</sup> while dietary history interviews were used in 11 studies.<sup>(26–28, 31, 34, 37, 39, 44, 53, 56, 60)</sup> In order to estimate the dietary flavonoid intake, 8 studies used the Phenol-Explorer, 11 used the USDA (among which 2 used it in conjunction with

1  
2  
3 Phenol-Explorer) and 22 used other databases (Table 1 and Supporting information Table  
4  
5 S3). Based on the evaluation of the NOS criteria, the majority of the studies scored high  
6  
7 quality (NOS = 7 or more) (Supporting information Table S4).  
8  
9

### 10 11 *Association between flavonoid intake and CVD*

12  
13 The summary RR for the highest versus the lowest category of total flavonoid intake from 8  
14  
15 cohorts was 0.81 (95% CI: 0.71-0.91), with moderate heterogeneity ( $I^2 = 62\%$ ) and no  
16  
17 publication bias ( $p = 0.073$  from Egger's test) (Figure 2 and Supporting information Figure  
18  
19 S1). Among individual main classes of flavonoids, individuals with the highest intake of  
20  
21 flavonols (RR = 0.85, 95% CI: 0.79-0.91;  $I^2 = 28\%$ ), flavanones (RR = 0.88, 95% CI: 0.79-  
22  
23 0.98;  $I^2 = 63\%$ ), flavan-3-ols (RR = 0.85, 95% CI: 0.76-0.95;  $I^2 = 67\%$ ), catechins (RR =  
24  
25 0.75, 95% CI: 0.63-0.89;  $I^2 = 0\%$ ), proanthocyanidins (RR = 0.83, 95% CI: 0.73-0.95;  $I^2 =$   
26  
27 54%), and anthocyanins (RR = 0.82, 95% CI: 0.70-0.96;  $I^2 = 75\%$ ) showed lower risk of  
28  
29 CVD compared to those with the lowest intake; however, only results for flavonol intake  
30  
31 were consistent and showed no heterogeneity (Table 2, Supporting Information Figure S2).  
32  
33 No publication bias was detected for all analyses except for small asymmetry of funnel plot  
34  
35 for proanthocyanidins (evidence from Egger's test is limited due to small number of studies  
36  
37 included) (Supporting information Figure S3).  
38  
39  
40  
41  
42  
43

44 The dose-response analysis performed on 8 cohorts showed a linear decreased risk of CVD  
45  
46 for increasing intake of flavonoid intake (Figure 3); compared to hypothetical no  
47  
48 consumption, intake up to 500 mg/d of total flavonoids was associated with 27% lower risk  
49  
50 of CVD (RR = 0.73, 95% CI: 0.62-0.86) despite with evidence of moderate heterogeneity  
51  
52 among results ( $I^2 = 51\%$ ) (Table 3). The subgroup analysis by CVD outcome revealed that  
53  
54 risk for both CVD incidence and mortality was reduced with increasing intake of total  
55  
56 flavonoids, despite wider CIs have been observed for the former (Table 3). Among individual  
57  
58  
59  
60

1  
2  
3 main classes of flavonoids (Supporting information Table S5), anthocyanins and flavan-3-ols  
4  
5 showed a linear decreasing risk of CVD for higher intakes, with small/moderate evidence of  
6  
7 heterogeneity (RR = 0.90, 95% CI: 0.83-0.98;  $I^2 = 48\%$  and RR = 0.91, 95% CI: 0.83-1.00  
8  
9 for 200 mg/d of flavan-3-ols,  $I^2 = 59\%$ ). Only one study supplied data sufficient to calculate a  
10  
11 dose-response for individual compounds and showed a decreasing risk of CVD for higher  
12  
13 intake of kaempferol (RR = 0.75, 95% CI: 0.56-1.00).  
14  
15  
16  
17

#### 18 *Association between flavonoid intake and CHD*

19  
20 In the meta-analysis comparing extreme categories, no association between total flavonoid  
21  
22 intake and CHD risk was observed (Figure 2). In contrast, a consistent relationship with  
23  
24 reduced risk of CHD was observed in studies exploring the intake of flavonols and flavones  
25  
26 (RR = 0.86, 95% CI: 0.77-0.97;  $I^2 = 34\%$ ), catechins (RR = 0.81, 95% CI: 0.68-0.97;  $I^2 =$   
27  
28  $0\%$ ), proanthocyanidins (RR = 0.79, 95% CI: 0.65-0.97;  $I^2 = 50\%$ ), and anthocyanins (RR =  
29  
30  $0.79$ , 95% CI: 0.64-0.98;  $I^2 = 66\%$ ), and a marginally significant association with large CIs  
31  
32 was shown in studies exploring the intake of flavonols (RR = 0.90, 95% CI: 0.80-1.01;  $I^2 =$   
33  
34  $0\%$ ) and flavan-3-ols (RR = 0.93, 95% CI: 0.86-1.01;  $I^2 = 0\%$ ). Small asymmetry of funnel  
35  
36 plot was detected only for anthocyanidins, despite the limited number of studies investigated  
37  
38 and the low power of Egger's test (Supporting information Figure S3). Among individual  
39  
40 compounds, individuals with higher intake of both quercetin and kaempferol (in borderline)  
41  
42 had lower risk of CHD, with no evidence of heterogeneity nor publication bias, despite the  
43  
44 wide CIs (Table 2, Supporting Information Figure S2).  
45  
46  
47  
48  
49  
50

51 The dose-response analysis showed a decreasing risk of CHD for higher intake of total  
52  
53 flavonoids, despite the association was not linear, reaching a plateau for 400 mg/d (RR =  
54  
55  $0.75$ , 95% CI: 0.61-0.94;  $I^2 = 1.0\%$ ; Table 3 and Figure 3). Both CHD incidence and  
56  
57 mortality risk were decreased with higher intake of flavonoids, despite nonsignificant results  
58  
59  
60

1  
2  
3 for the highest intake and a nonlinear association were evident for the latter (Table 3). Among  
4 individual classes of flavonoids, the strongest association with decreasing risk of CHD for  
5 higher intake of flavonols and flavones was found with an optimal intake equal to 18-24  
6 mg/d (RR = 0.88, 95% CI: 0.81-0.97; for 30 mg/d of intake,  $I^2 = 1\%$ ; Supporting information  
7 Table S6). Among individual compounds, the summary risk estimates from 5 studies showed  
8 a decreased risk of CHD for higher intake of quercetin, despite the association with the  
9 lowest risk was observed for up to 12-14 mg/d (RR = 0.72, 95% CI: 0.66-0.78; for 12 mg/d of  
10 intake,  $I^2 = 1\%$ ; Supporting information Table S5).

#### 21 22 *Association between flavonoid intake and stroke*

23  
24 The highest consumption of total flavonoids was not associated with a significant change of  
25 stroke risk compared to no consumption (Figure 2); among individual subgroups of  
26 flavonoids, flavanones intake was associated with 14% reduced risk of stroke (RR = 0.86,  
27 95% CI: 0.77-0.96) with no evidence of heterogeneity ( $I^2 = 0\%$ ) nor publication bias (Table  
28 2, Supporting Information Figure S2 and Supporting information Figure S3). Also, higher  
29 intake of catechins was associated inversely with risk of stroke (RR = 0.70, 95% CI: 0.55-  
30 0.88;  $I^2 = 0\%$ ). Among individual compounds, two studies showed that individuals with a  
31 higher intake of kaempferol were less likely to have stroke compared to those with lower  
32 intake (RR = 0.72, 95% CI: 0.59-0.88,  $I^2 = 0\%$ ; Table 2, Supporting Information Figure S2).

33  
34 The dose-response analysis demonstrated a decreasing risk of stroke for higher intake of total  
35 flavonoids up to 400 mg/d (RR = 0.79, 95% CI: 0.63-1.00 for 400 mg/d of intake), with no  
36 evidence of heterogeneity ( $I^2 = 1\%$ ); when considering stroke incidence and mortality risk  
37 separately, a marginally significant association was observed for the former (Table 3).

38  
39 Among individual compounds, only flavones and flavanones consumption was associated  
40 with reduced risk of stroke with a decreasing trend across higher intake. Significant results  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 were found for 1.2-1.6 mg/d intake of flavones (RR = 0.37, 95% CI: 0.22-0.64; for 1.6 mg/d),  
4  
5 but a high between studies heterogeneity was observed ( $I^2 = 98\%$ ), and for up to 36 mg/d  
6  
7 intake of flavanones (RR = 0.79, 95% CI: 0.63-0.98;  $I^2 = 1\%$ ; Supporting information Table  
8  
9 S5).

#### 11 12 13 *Association between lignan intake and CVD outcomes*

14  
15 Higher dietary intake of lignan was not associated with lower risk of none of the explored  
16  
17 outcomes including CVD (RR = 0.82, 95% CI: 0.65-1.04;  $I^2 = 40\%$ ), CHD (RR = 0.82, 95%  
18  
19 CI: 0.65-1.01;  $I^2 = 1.0\%$ ), and stroke (RR = 0.92, 95% CI: 0.71-1.19;  $I^2 = 0\%$ ). Similar results  
20  
21 were found when exploring the dose-response association between dietary lignan intake and  
22  
23 risk of cardiovascular outcomes (Supporting Information Table S5).

#### 24 25 26 27 28 *Stratified and subgroup analyses*

29  
30 In order to evaluate stability of the results and role of potential confounding factors, a  
31  
32 sensitivity analysis by excluding one study at a time (data not shown) and by excluding  
33  
34 studies with no complete data on number of cases/person-years, as well as stratified analyses,  
35  
36 were performed and revealed no substantial differences from the main analysis (Supporting  
37  
38 information Table S6).

39  
40  
41  
42  
43 Subgroup analyses for the association between total flavonoid intake and CVD risk  
44  
45 (fatal/non-fatal) are reported in Table 4. The results were mainly stable across most  
46  
47 subgroups, including CVD outcome (incidence/mortality), location (US/Europe), follow-up  
48  
49 (10-year cut off), adjustment for energy intake and other dietary factors. Moreover, subgroup  
50  
51 analysis by sex depicted marginally significant results only for women (Table 4). Although  
52  
53 studies adjusting for BMI showed a decreased risk of CVD when compared to those not  
54  
55 adjusting, a different result was observed for adjustment for type-2 diabetes. Specifically, a  
56  
57  
58  
59  
60

1  
2  
3 decreased risk of CVD for higher intake of flavonoids was found in studies not adjusting for  
4 type-2 diabetes, but lack of association was found in those that adjusted the results (Table 4).  
5  
6  
7  
8  
9

## 10 **Discussion**

11  
12 In this comprehensive meta-analysis, we found that higher dietary intake of total flavonoids is  
13 associated with lower risk of CVD in a linear manner (with the highest intake calculated at  
14 500 mg/d); specific CVD outcomes were both CHD and stroke, despite the lowest risk was  
15 reached at 400 mg/d for the former. Among the main classes of flavonoids investigated,  
16 anthocyanins and flavan-3-ols are the best candidate to provide the strongest protection  
17 against CVD, while higher intake of flavonols and flavones resulted associated with lower  
18 risk of CHD; regarding stroke risk, flavanones were the most relevant class, despite the  
19 lowest risk was reached for relatively low consumption. Among individual compounds,  
20 intakes of quercetin and kaempferol were linearly associated with lower risk of CHD and  
21 CVD, respectively. Finally, higher dietary intake of lignan has not been significantly  
22 associated with none of the investigated outcomes, however possibly due to the limited  
23 number of analyzed studies. These findings significantly update results from previous meta-  
24 analyses, which had several limitations, including lack of focus on individual compounds or  
25 specific cardiovascular outcomes (i.e., only stroke or CHD), misclassification of flavonoid  
26 groups, and lack of dose-response analysis.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 The results of this study support the evidence provided by meta-analyses of clinical  
50 randomized controlled trials (RCTs) on total and individual classes of flavonoids and major  
51 cardiovascular intermediary biomarkers.<sup>(65)</sup> Among them, flavan-3-ols have been  
52 demonstrated to improve flow-mediated dilation (FMD), considered the gold standard  
53 measure of endothelial function, blood lipids levels, systolic and diastolic blood pressure, and  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 HOMA-IR.<sup>(19)</sup> Also meta-analyses of RCTs on anthocyanins and anthocyanin-rich foods  
4 showed significant improvements in glycemic control and blood lipids levels,<sup>(66)</sup> as well as  
5 FMD and pulse wave velocity,<sup>(67)</sup> supporting the benefits of anthocyanins in the prevention  
6 and management of cardiometabolic disease. Evidence from RCTs on flavonols showed  
7 improvement in cardiometabolic biomarkers, including reduction of total cholesterol, LDL  
8 cholesterol, triacylglycerol, fasting plasma glucose, blood pressure, and an increase in HDL  
9 cholesterol.<sup>(68)</sup>

10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21 Various mechanisms providing the rationale for the potential protective effects of dietary  
22 flavonoids on cardiovascular health have been described.<sup>(69)</sup> Flavonoids have proved to  
23 enhance the bioavailability and bioactivity of nitric oxide (NO) and other vascular relaxing  
24 factors (such as endothelium-derived hyperpolarizing factor and prostacyclin), which in turn  
25 might ameliorate vascular parameters, including vasodilation, platelet adhesion, and smooth  
26 muscle proliferation in the vessel wall.<sup>(70)</sup> Moreover, flavonoids have been shown to exert  
27 antioxidant and anti-inflammatory actions by modulating the expression of proteins involved  
28 in the control the anti-inflammatory nuclear factor erythroid 2-related factor 2 (Nrf2) pathway  
29 and the pro-inflammatory nuclear factor kappa-light-chain-enhancer of activated B cells (NF-  
30 K $\beta$ ) pathway, which it turn may lead to free radical scavenging, inhibition of the activity  
31 and/or expression of pro-inflammatory enzymes, and down-regulation of pro-inflammatory  
32 mediators (such as tumor necrosis factor-alpha TNF- $\alpha$ , interleukin IL-1b, and IL-6).<sup>(71)</sup>  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49 Finally, it has been also hypothesized that intake of dietary flavonoid may affect gut  
50 microbiome, which through the modulation of inflammation may influence biomarkers of  
51 cardiovascular risk.<sup>(72)</sup>  
52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 The present study has a number of strengths, as i) it included analyses for the highest number  
4 of compounds (subgroups and individual flavonoids) with a dose-response approach; ii) a  
5 proper evaluation of the exposure allowed for a correct classification of flavonoid groups,  
6 avoiding inaccurate comparisons; iii) the investigated outcomes allowed separating CVD risk  
7 and mortality, as well as specific subgroups of disease (CHD and stroke). However, the  
8 proposed findings should be also considered in light of some limitations. First, they are based  
9 on risk estimates extracted from observational population studies, which do not allow to fully  
10 assess a cause-effect relation; thus, the retrieved association may still be suffering from  
11 reverse causation, unmeasured confounding factors (including the role of potential effect  
12 modifiers and multicollinearity), and lack of adjustment for covariates potentially affecting  
13 the association. Second, although intuitive, it should be acknowledged that bioactive  
14 compounds are likely to also act synergistically with other compounds present in plant-based  
15 foods such as fiber, vitamins and other bioactive compounds, and that their effects may  
16 depend on the pattern of food consumed and on personal host microbiota, with a certain  
17 degree of inter-person variability in absorption, metabolism, and activity of dietary  
18 flavonoids that cannot be eliminated from this type of studies. Third, data on polyphenols  
19 included in the examined studies is estimated from FFQs or dietary recalls and then  
20 calculated from food composition databases, which may lead to two important limitations  
21 (besides the potential recall bias): the databases used in some studies may be outdated,  
22 lacking in some food sources of flavonoids or on retention factor for each group of  
23 compounds following cooking or variability directly related to food quality (plant variety,  
24 season and environmental factors, food storage and processing); and (ii) the current  
25 methodology does not take into account the metabolism and transformation of flavonoids  
26 after ingestion, thus potentially missing the identification of the compounds that really exert  
27 the desired effects.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 In conclusions, the results of this study provide further evidence of the potentiality of a  
4 flavonoid-rich diet toward CVDs prevention. Plant-based diets with selected key foods might  
5 represent a valuable resource against the rising trends of the world's leading cause of death.  
6  
7 Nevertheless, future research on flavonoids should focus also on inter-individual variability  
8 in the flavonoid metabolism linked to gut microbiome and nutrients interactions and aiming  
9 to explore not only dietary intake but also true exposure to their metabolites conditioned on  
10 the microbial species diversity.  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20

21 **Author contributions:** conceptualization and methodology, A.M., J.G., G.G.; formal  
22 analysis and data curation, A.M., G.G.; writing, review and editing, A.M. J.G., D.D.R., F.G.,  
23 G.G.  
24  
25  
26  
27  
28

29 **Conflict of interest:** Authors declare that there is no conflict of interest.  
30

31 **Acknowledgments:** Icons used in the graphical abstract are made  
32 by Freepik from [www.flaticon.com](http://www.flaticon.com).  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure legend**

Figure 1. Flow chart of study selection process.

Figure 2. Summary relative risks for the highest *versus* the lowest category of total flavonoid intake and risk of cardiovascular disease, coronary heart disease and stroke.

Figure 3. Graphical representation of dose-response meta-analysis for total flavonoid intake and risk of cardiovascular disease, coronary heart disease and stroke.

**Table legend**

Table 1. Main characteristics of included studies in the meta-analysis.

Table 2. Summary relative risks for the highest *versus* the lowest category of individual classes of flavonoids and lignan intake and risk of cardiovascular disease, coronary heart disease and stroke.

Table 3. Dose-response meta-analysis for total flavonoid intake and risk of cardiovascular disease, coronary heart disease and stroke.

Table 4. Subgroup analyses by potential confounding factors for the association between the highest *versus* the lowest intake of total flavonoids and cardiovascular disease risk.

**Supporting information legend**

Supporting information Table S1. The Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines.

Supporting information Table S2. Search strategy.

Supporting information Table S3. Characteristics of tools and measurements used to assess dietary intake in meta-analysed studies.

Supporting information Table S4. Assessment of quality of included studies using the Newcastle-Ottawa Quality Assessment Scale (NOS).

1  
2  
3 Supporting information Table S5. Dose-response meta-analysis of the association between  
4 individual classes of flavonoids intake and cardiovascular outcomes in prospective cohort  
5 studies.  
6  
7  
8  
9

10 Supporting information Table S6. Dose-response meta-analysis of the association between  
11 individual classes of flavonoids intake and cardiovascular outcomes in prospective cohort  
12 studies restricted only to studies with complete data about cases and person-years for each  
13 category of intake.  
14  
15  
16  
17  
18  
19

20 Supporting information Figure S1. Funnel plots for meta-analysis for the highest *versus* the  
21 lowest category of total flavonoid intake and risk of cardiovascular disease, coronary heart  
22 disease and stroke.  
23  
24  
25  
26

27 Supporting information Figure S2. Forest plots for meta-analysis for the highest versus the  
28 lowest category of the individual classes of flavonoid intake and risk of cardiovascular  
29 disease, coronary heart disease and stroke.  
30  
31  
32  
33

34 Supporting information Figure S3. Funnel plots for meta-analysis for the highest *versus* the  
35 lowest category of individual classes of flavonoids and lignan intake and risk of  
36 cardiovascular disease, coronary heart disease and stroke.  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## References

1. GBD, Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. **392**, 1736–1788 (2018).
2. GBD 2017 Risk Factor Collaborators, Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. **392**, 1923–1994 (2018).
3. D. Angelino *et al.*, Fruit and vegetable consumption and health outcomes: an umbrella review of observational studies. *Int. J. Food Sci. Nutr.* **70**, 652–667 (2019).
4. L. Schwingshackl *et al.*, Impact of different types of olive oil on cardiovascular risk factors: A systematic review and network meta-analysis. *Nutr. Metab. Cardiovasc. Dis.* **29**, 1030–1039 (2019).
5. L. Schwingshackl, G. Hoffmann, B. Missbach, M. Stelmach-Mardas, H. Boeing, An umbrella review of nuts intake and risk of cardiovascular disease. *Curr. Pharm. Des.* **23**, 1016–1027 (2017).
6. M. Tieri *et al.*, Whole grain consumption and human health: an umbrella review of observational studies. *Int. J. Food Sci. Nutr.* **71**, 668–677 (2020).
7. N. Veronese *et al.*, Is chocolate consumption associated with health outcomes? An umbrella review of systematic reviews and meta-analyses. *Clin. Nutr.* **38**, 1101–1108 (2019).
8. G. Grosso, J. Godos, F. Galvano, E. L. Giovannucci, Coffee, caffeine, and health outcomes: an umbrella review. *Annu. Rev. Nutr.* **37**, 131–156 (2017).
9. M. Yi *et al.*, Tea Consumption and Health Outcomes: Umbrella Review of Meta-Analyses of Observational Studies in Humans. *Mol. Nutr. Food Res.* **63**, e1900389 (2019).

10. GBD 2017 Diet Collaborators, Health effects of dietary risks in 195 countries, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. **393**, 1958–1972 (2019).
11. D. Martini *et al.*, Claimed effects, outcome variables and methods of measurement for health claims proposed under European Community Regulation 1924/2006 in the framework of protection against oxidative damage and cardiovascular health. *Nutr. Metab. Cardiovasc. Dis.* **27**, 473–503 (2017).
12. D. Del Rio *et al.*, Dietary (poly)phenolics in human health: structures, bioavailability, and evidence of protective effects against chronic diseases. *Antioxid. Redox Signal.* **18**, 1818–1892 (2013).
13. G. Grosso *et al.*, Dietary Flavonoid and Lignan Intake and Mortality in Prospective Cohort Studies: Systematic Review and Dose-Response Meta-Analysis. *Am. J. Epidemiol.* **185**, 1304–1316 (2017).
14. J. Godos *et al.*, Dietary Polyphenol Intake, Blood Pressure, and Hypertension: A Systematic Review and Meta-Analysis of Observational Studies. *Antioxidants (Basel)*. **8** (2019), doi:10.3390/antiox8060152.
15. A. Micek *et al.*, Dietary phytoestrogens and biomarkers of their intake in relation to cancer survival and recurrence: a comprehensive systematic review with meta-analysis. *Nutr. Rev.* (2020), doi:10.1093/nutrit/nuaa043.
16. A. González-Sarrías *et al.*, A Systematic Review and Meta-Analysis of the Effects of Flavanol-Containing Tea, Cocoa and Apple Products on Body Composition and Blood Lipids: Exploring the Factors Responsible for Variability in Their Efficacy. *Nutrients*. **9**, 746 (2017).
17. L. Hooper *et al.*, Flavonoids, flavonoid-rich foods, and cardiovascular risk: a meta-analysis of randomized controlled trials. *Am. J. Clin. Nutr.* **88**, 38–50 (2008).

- 1  
2  
3 18. L. Ellwood, G. Torun, Z. Bahar, R. Fernandez, Effects of flavonoid rich fruits on  
4 hypertension in adults: a systematic review. *JBI Database System. Rev. Implement. Rep.*  
5  
6 (2019), doi:10.11124/JBISRIR-D-19-00050.  
7  
8
- 9  
10 19. G. Raman *et al.*, Dietary intakes of flavan-3-ols and cardiometabolic health:  
11 systematic review and meta-analysis of randomized trials and prospective cohort studies. *Am.*  
12  
13 *J. Clin. Nutr.* **110**, 1067–1078 (2019).  
14  
15
- 16 20. B. H. Parmenter *et al.*, An overview and update on the epidemiology of flavonoid  
17 intake and cardiovascular disease risk. *Food Funct.* **11**, 6777–6806 (2020).  
18  
19
- 20 21. X. Wang, Y. Y. Ouyang, J. Liu, G. Zhao, Flavonoid intake and risk of CVD: a  
21 systematic review and meta-analysis of prospective cohort studies. *Br. J. Nutr.* **111**, 1–11  
22  
23 (2014).  
24  
25
- 26 22. A. Stang, Critical evaluation of the Newcastle-Ottawa scale for the assessment of the  
27 quality of nonrandomized studies in meta-analyses. *Eur. J. Epidemiol.* **25**, 603–605 (2010).  
28  
29
- 30 23. N. Orsini, R. Li, A. Wolk, P. Khudyakov, D. Spiegelman, Meta-analysis for linear  
31 and nonlinear dose-response relations: examples, an evaluation of approximations, and  
32 software. *Am. J. Epidemiol.* **175**, 66–73 (2012).  
33  
34  
35  
36  
37  
38  
39
- 40 24. S. Greenland, M. P. Longnecker, Methods for trend estimation from summarized  
41 dose-response data, with applications to meta-analysis. *Am. J. Epidemiol.* **135**, 1301–1309  
42  
43 (1992).  
44  
45
- 46 25. N. Orsini, R. Bellocco, S. Greenland, Generalized least squares for trend estimation of  
47 summarized dose–response data. *The Stata Journal.* **6**, 40–57 (2006).  
48  
49
- 50 26. M. G. Hertog, E. J. Feskens, P. C. Hollman, M. B. Katan, D. Kromhout, Dietary  
51 antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. *Lancet.*  
52  
53 **342**, 1007–1011 (1993).  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 27. S. O. Keli, M. G. Hertog, E. J. Feskens, D. Kromhout, Dietary flavonoids, antioxidant  
4 vitamins, and incidence of stroke: the Zutphen study. *Arch. Intern. Med.* **156**, 637–642  
5  
6 (1996).  
7  
8  
9  
10 28. P. Knekt, R. Jarvinen, A. Reunanen, J. Maatela, Flavonoid intake and coronary  
11 mortality in Finland: a cohort study. *BMJ.* **312**, 478–481 (1996).  
12  
13  
14 29. E. B. Rimm, M. B. Katan, A. Ascherio, M. J. Stampfer, W. C. Willett, Relation  
15 between intake of flavonoids and risk for coronary heart disease in male health professionals.  
16  
17 *Ann. Intern. Med.* **125**, 384–389 (1996).  
18  
19  
20 30. M. G. Hertog, E. J. Feskens, D. Kromhout, Antioxidant flavonols and coronary heart  
21 disease risk. *Lancet.* **349**, 699 (1997).  
22  
23  
24 31. M. G. Hertog, P. M. Sweetnam, A. M. Fehily, P. C. Elwood, D. Kromhout,  
25 Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the  
26  
27 Caerphilly Study. *Am. J. Clin. Nutr.* **65**, 1489–1494 (1997).  
28  
29  
30 32. L. Yochum, L. H. Kushi, K. Meyer, A. R. Folsom, Dietary flavonoid intake and risk  
31 of cardiovascular disease in postmenopausal women. *Am. J. Epidemiol.* **149**, 943–949 (1999).  
32  
33  
34 33. T. Hirvonen, J. Virtamo, P. Korhonen, D. Albanes, P. Pietinen, Intake of flavonoids,  
35 carotenoids, vitamins C and E, and risk of stroke in male smokers. *Stroke.* **31**, 2301–2306  
36  
37 (2000).  
38  
39  
40 34. I. C. Arts, P. C. Hollman, E. J. Feskens, H. B. Bueno de Mesquita, D. Kromhout,  
41 Catechin intake might explain the inverse relation between tea consumption and ischemic  
42  
43 heart disease: the Zutphen Elderly Study. *Am. J. Clin. Nutr.* **74**, 227–232 (2001).  
44  
45  
46 35. I. C. Arts, D. R. Jacobs, L. J. Harnack, M. Gross, A. R. Folsom, Dietary catechins in  
47  
48 relation to coronary heart disease death among postmenopausal women. *Epidemiology.* **12**,  
49  
50 668–675 (2001).  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1  
2  
3 36. J. M. Geleijnse, L. J. Launer, D. A. M. Van der Kuip, A. Hofman, J. C. M. Witteman,  
4  
5 Inverse association of tea and flavonoid intakes with incident myocardial infarction: the  
6  
7 Rotterdam Study. *Am. J. Clin. Nutr.* **75**, 880–886 (2002).  
8  
9  
10 37. P. Knekt *et al.*, Flavonoid intake and risk of chronic diseases. *Am. J. Clin. Nutr.* **76**,  
11  
12 560–568 (2002).  
13  
14 38. H. D. Sesso, J. M. Gaziano, S. Liu, J. E. Buring, Flavonoid intake and the risk of  
15  
16 cardiovascular disease in women. *Am. J. Clin. Nutr.* **77**, 1400–1408 (2003).  
17  
18  
19 39. J. Marniemi *et al.*, Dietary and serum vitamins and minerals as predictors of  
20  
21 myocardial infarction and stroke in elderly subjects. *Nutr. Metab. Cardiovasc. Dis.* **15**, 188–  
22  
23 197 (2005).  
24  
25  
26 40. Y. T. van der Schouw *et al.*, Prospective study on usual dietary phytoestrogen intake  
27  
28 and cardiovascular disease risk in Western women. *Circulation.* **111**, 465–471 (2005).  
29  
30  
31 41. J. Lin *et al.*, Dietary intakes of flavonols and flavones and coronary heart disease in  
32  
33 US women. *Am. J. Epidemiol.* **165**, 1305–1313 (2007).  
34  
35  
36 42. Y. Kokubo *et al.*, Association of dietary intake of soy, beans, and isoflavones with  
37  
38 risk of cerebral and myocardial infarctions in Japanese populations: the Japan Public Health  
39  
40 Center-based (JPHC) study cohort I. *Circulation.* **116**, 2553–2562 (2007).  
41  
42  
43 43. P. J. Mink *et al.*, Flavonoid intake and cardiovascular disease mortality: a prospective  
44  
45 study in postmenopausal women. *Am. J. Clin. Nutr.* **85**, 895–909 (2007).  
46  
47  
48 44. J. Mursu *et al.*, Flavonoid intake and the risk of ischaemic stroke and CVD mortality  
49  
50 in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Br. J.*  
51  
52 *Nutr.* **100**, 890–895 (2008).  
53  
54 45. A. Cassidy *et al.*, Dietary flavonoids and risk of stroke in women. *Stroke.* **43**, 946–951  
55  
56 (2012).  
57  
58  
59  
60

- 1  
2  
3 46. M. L. McCullough *et al.*, Flavonoid intake and cardiovascular disease mortality in a  
4 prospective cohort of US adults. *Am. J. Clin. Nutr.* **95**, 454–464 (2012).  
5  
6  
7  
8 47. A. Cassidy *et al.*, High anthocyanin intake is associated with a reduced risk of  
9 myocardial infarction in young and middle-aged women. *Circulation.* **127**, 188–196 (2013).  
10  
11  
12 48. M. Talaei, W.-P. Koh, R. M. van Dam, J.-M. Yuan, A. Pan, Dietary soy intake is not  
13 associated with risk of cardiovascular disease mortality in Singapore Chinese adults. *J. Nutr.*  
14 **144**, 921–928 (2014).  
15  
16  
17 49. A. Tresserra-Rimbau *et al.*, Inverse association between habitual polyphenol intake  
18 and incidence of cardiovascular events in the PREDIMED study. *Nutr. Metab. Cardiovasc.*  
19 *Dis.* **24**, 639–647 (2014).  
20  
21  
22 50. D. Yu *et al.*, Association of soy food intake with risk and biomarkers of coronary  
23 heart disease in Chinese men. *Int. J. Cardiol.* **172**, e285-7 (2014).  
24  
25  
26 51. K. L. Ivey, J. M. Hodgson, K. D. Croft, J. R. Lewis, R. L. Prince, Flavonoid intake  
27 and all-cause mortality. *Am. J. Clin. Nutr.* **101**, 1012–1020 (2015).  
28  
29  
30 52. V. Ponzio *et al.*, Dietary flavonoid intake and cardiovascular risk: a population-based  
31 cohort study. *J. Transl. Med.* **13**, 218 (2015).  
32  
33  
34 53. A. Vogiatzoglou *et al.*, Associations between flavan-3-ol intake and CVD risk in the  
35 Norfolk cohort of the European Prospective Investigation into Cancer (EPIC-Norfolk). *Free*  
36 *Radic. Biol. Med.* **84**, 1–10 (2015).  
37  
38  
39 54. D. Yu *et al.*, Dietary isoflavones, urinary isoflavonoids, and risk of ischemic stroke in  
40 women. *Am. J. Clin. Nutr.* **102**, 680–686 (2015).  
41  
42  
43 55. A. Cassidy *et al.*, Habitual intake of anthocyanins and flavanones and risk of  
44 cardiovascular disease in men. *Am. J. Clin. Nutr.* **104**, 587–594 (2016).  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3 56. J. I. Dower, J. M. Geleijnse, P. C. Hollman, S. S. Soedamah-Muthu, D. Kromhout,  
4 Dietary epicatechin intake and 25-y risk of cardiovascular mortality: the Zutphen Elderly  
5 Study. *Am. J. Clin. Nutr.* **104**, 58–64 (2016).  
6  
7  
8  
9  
10 57. M. E. Goetz *et al.*, Dietary flavonoid intake and incident coronary heart disease: the  
11 REasons for Geographic and Racial Differences in Stroke (REGARDS) study. *Am. J. Clin.*  
12 *Nutr.* **104**, 1236–1244 (2016).  
13  
14  
15  
16  
17 58. M. E. Goetz *et al.*, Flavanone Intake Is Inversely Associated with Risk of Incident  
18 Ischemic Stroke in the REasons for Geographic and Racial Differences in Stroke  
19 (REGARDS) Study. *J. Nutr.* **146**, 2233–2243 (2016).  
20  
21  
22  
23  
24 59. C. Nagata *et al.*, Dietary soy and natto intake and cardiovascular disease mortality in  
25 Japanese adults: the Takayama study. *Am. J. Clin. Nutr.* **105**, 426–431 (2017).  
26  
27  
28  
29 60. S. Adriouch *et al.*, Prospective Association between Total and Specific Dietary  
30 Polyphenol Intakes and Cardiovascular Disease Risk in the Nutrinet-Santé French Cohort.  
31 *Nutrients.* **10** (2018), doi:10.3390/nu10111587.  
32  
33  
34  
35 61. N. P. Bondonno *et al.*, Flavonoid intake is associated with lower mortality in the  
36 Danish Diet Cancer and Health Cohort. *Nat. Commun.* **10**, 3651 (2019).  
37  
38  
39  
40 62. F. Dalgaard *et al.*, Associations between habitual flavonoid intake and hospital  
41 admissions for atherosclerotic cardiovascular disease: a prospective cohort study. *Lancet*  
42 *Planet. Health.* **3**, e450–e459 (2019).  
43  
44  
45  
46 63. R. D. Mendonça *et al.*, Total polyphenol intake, polyphenol subtypes and incidence of  
47 cardiovascular disease: The SUN cohort study. *Nutr. Metab. Cardiovasc. Dis.* **29**, 69–78  
48 (2019).  
49  
50  
51  
52  
53 64. T. Hirvonen *et al.*, Intake of flavonols and flavones and risk of coronary heart disease  
54 in male smokers. *Epidemiology.* **12**, 62–67 (2001).  
55  
56  
57  
58  
59  
60

- 1  
2  
3 65. M. Marino, C. Del Bo', D. Martini, M. Porrini, P. Riso, A review of registered  
4 clinical trials on dietary (poly)phenols: past efforts and possible future directions. *Foods*. **9**  
5 (2020), doi:10.3390/foods9111606.  
6  
7  
8  
9  
10 66. L. Yang *et al.*, Effects of Anthocyanins on Cardiometabolic Health: A Systematic  
11 Review and Meta-Analysis of Randomized Controlled Trials. *Adv. Nutr.* **8**, 684–693 (2017).  
12  
13 67. L. Fairlie-Jones, K. Davison, E. Fromentin, A. M. Hill, The Effect of Anthocyanin-  
14 Rich Foods or Extracts on Vascular Function in Adults: A Systematic Review and Meta-  
15 Analysis of Randomised Controlled Trials. *Nutrients*. **9** (2017), doi:10.3390/nu9080908.  
16  
17 68. R. Menezes *et al.*, Impact of Flavonols on Cardiometabolic Biomarkers: A Meta-  
18 Analysis of Randomized Controlled Human Trials to Explore the Role of Inter-  
19 Individual Variability. *Nutrients*. **9** (2017), doi:10.3390/nu9020117.  
20  
21 69. F. Perez-Vizcaino, J. Duarte, Flavonols and cardiovascular disease. *Mol. Aspects*  
22 *Med.* **31**, 478–494 (2010).  
23  
24 70. B. Almeida Rezende, A. C. Pereira, S. F. Cortes, V. S. Lemos, Vascular effects of  
25 flavonoids. *Curr. Med. Chem.* **23**, 87–102 (2016).  
26  
27 71. R. M. da Costa *et al.*, Nrf2 as a potential mediator of cardiovascular risk in metabolic  
28 diseases. *Front. Pharmacol.* **10**, 382 (2019).  
29  
30 72. E. Salvucci, The human-microbiome superorganism and its modulation to restore  
31 health. *Int. J. Food Sci. Nutr.* **70**, 781–795 (2019).  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Table 1. Main characteristics of included studies in the meta-analysis.

Author, year	Cohort name, country	Follow-up	Population’s characteristic	Age at baseline	N & sex	Outcomes	Cases
Hertog, 1993 <sup>(26)</sup>	Zutphen Elderly Study, Netherlands	4.6y (median)	Residents of Zutphen	65-84	M 805	CHD (fatal, fatal and nonfatal)	73 CHD
Keli, 1996 <sup>(27)</sup>	Zutphen Elderly Study, Netherlands	15y	Residents of Zutphen	50-69	M 552	Stroke (fatal and nonfatal)	42 Stroke
Knekt, 1996 <sup>(28)</sup>	Finnish Social Insurance Institution, Finland	26y	Population-based	30-68	M 2,748	CHD (fatal)	473 CHD
Rimm, 1996 <sup>(29)</sup>	Health Professionals Follow-up Study, US	6y	Men in health professions	40-75	M 34,789	MI (nonfatal)	486 MI
Hertog, 1997 <sup>(31)</sup>	Caerphilly Study, Wales	14y	Residents of Caerphilly	45-59	M 1,900	CHD (fatal and nonfatal; fatal)	186 CHD
Hertog, 1997 <sup>(30)</sup>	Zutphen Elderly Study, Netherlands	10y	Residents of Zutphen	65-84	M 804	CHD (fatal); MI (fatal and nonfatal)	90 CHD
Yochum, 1999 <sup>(32)</sup>	Iowa Women’s Health Study, US	10y (median)	Postmenopausal women with valid Iowa drivers licenses	55-69	F 34,492	CHD (fatal)	438 CHD
Hirvonen, 2000 <sup>(33)</sup>	Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Finland	6.1y (median)	Male smokers	50-69	M 26,593	Stroke (fatal and nonfatal)	736 Stroke
Arts, 2001 <sup>(34)</sup>	Zutphen Elderly Study, Netherlands	10y, 7.5y (median)	Residents of Zutphen	65-84	M 806	CHD (fatal); MI (fatal and nonfatal)	180 CHD
Arts, 2001 <sup>(35)</sup>	Iowa Women’s Health Study, US	10y	Postmenopausal women with valid Iowa drivers licenses	55-69	F 34,492	CHD (fatal)	767 CHD
Hirvonen, 2001 <sup>(64)</sup>	Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study, Finland	5-8y, 6.1y (median)	Male smokers	50-69	M 25,372	MI (nonfatal); CHD (fatal)	1,937 MI
Geleijnse, 2002 <sup>(36)</sup>	Rotterdam Study, Netherlands	5.6y (median)	Residents of defined district of Rotterdam	55+	MF 4,807	MI (fatal and nonfatal; nonfatal; fatal)	146 MI
Knekt, 2002 <sup>(37)</sup>	Finnish Mobile Clinic Health Examination Survey, Finland	28y	Population-based	15+	MF 10,054	CHD (fatal); Stroke (fatal)	681 CHD; 806 Stroke
Sesso, 2003 <sup>(38)</sup>	Women’s Health Study, US	6.9y (median)	Health professionals	45+	MF 38,445	CVD (fatal and nonfatal)	729 CVD
Marniemi, 2005 <sup>(39)</sup>	Finnish elderly Study, Finland	R 10	Residents of city of Turku and surrounding rural areas	65-99	M 361, F 394	MI (fatal and nonfatal); Stroke (fatal and nonfatal)	130 MI; 70 Stroke
van der Schouw, 2005 <sup>(40)</sup>	Dutch Prospect-EPIC, Denmark	6.3y (median)	Population-based	49-70	F 16,165	CHD (fatal and nonfatal); Stroke (fatal and nonfatal); CVD (fatal and nonfatal)	372 CHD; 147 Stroke; 519 CVD
Lin, 2006 <sup>(41)</sup>	Nurses’ Health Study, US	12y	Registered nurses	30-55	F 66,369	MI (nonfatal); CHD (fatal)	1,262 MI
Kokubo, 2007 <sup>(42)</sup>	Japan Public Health Center–Based Study, Japan	12.5y (median)	Population-based	40-59	MF 40,462	Stroke (fatal and nonfatal); MI (fatal and nonfatal); CVD (fatal and nonfatal; fatal)	308 MI; 468 Stroke; 776 CVD
Mink, 2007 <sup>(43)</sup>	Iowa Women’s Health Study, US	16y	Postmenopausal women with valid Iowa drivers licenses	55-69	F 34,489	Stroke (fatal); CHD (fatal); CVD (fatal)	1,329 CHD; 469 Stroke; 2,316 CVD

1								
2								
3								
4	Mursu, 2008 <sup>(44)</sup>	Kuopio Ischaemic Heart Disease Risk Factor Study, Finland	15.2y (median)	Population-based	42-60	M 1,950	Stroke (fatal and nonfatal); CVD (fatal)	102 Stroke (ischemic); 153 CVD
5								
6	Cassidy, 2012 <sup>(45)</sup>	Nurses' Health Study, US	14y	Registered nurses	30-55	F 69,622	Stroke (fatal and nonfatal)	1,803 Stroke
7	McCullough, 2012 <sup>(46)</sup>	Cancer Prevention Study II Nutrition Cohort, US	7y	Population-based	30-55	M 38,180, F 60,289	CVD (fatal)	2771 CVD
8								
9	Cassidy, 2013 <sup>(47)</sup>	Nurses' Health Study II, US	18y	Registered nurses	25-42	F 93,600	MI (fatal and nonfatal)	405 MI
10	Talaei, 2014 <sup>(48)</sup>	Singapore Chinese Health Study, China	13.6y (median)	Population-based	45-74	MF 40,622	CVD (fatal); CHD (fatal); Stroke (fatal)	2,697 CHD; 1,298 Stroke; 4,780 CVD
11								
12	Tresserra-Rimbau, 2014 <sup>(49)</sup>	PREvención con Dieta MEDiterránea Study, Spain	4.3y (median)	Population-based	55-80	MF 7,172	CVD (fatal and nonfatal)	273 CVD
13								
14	Yu, 2014 <sup>(50)</sup>	Shanghai Men's Health Study, China	5.4y (median)	Population-based	40-74y	M 55,474	CHD (fatal and nonfatal)	217 CHD
15								
16	Ivey, 2015 <sup>(51)</sup>	Calcium Intake Fracture Outcome Age Related Extension Study, Australia	5y	Postmenopausal women	75+	F 1,063	CVD (fatal)	78 CVD
17								
18	Ponzo, 2015 <sup>(52)</sup>	Prospective Italian Study, Italy	12y (median)	Residents of the province of Asti	45-64	MF 1,877	CVD (nonfatal); CVD (fatal)	209 CVD
19								
20	Vogiatzoglou, 2015 <sup>(53)</sup>	European Prospective Investigation into Cancer and Nutrition-Norfolk Study, UK	11.5y (median)	Population-based	40-75	M 11,252, F 13,633	CVD (fatal and nonfatal); CHD (fatal and nonfatal); Stroke (fatal and nonfatal); CVD (fatal)	6,395 CHD; 1,920 Stroke; 5,557 CVD
21								
22	Yu, 2015 <sup>(54)</sup>	Shanghai Women's Health Study, China	10y (median)	Population-based	40-70	F 66,832	Stroke (fatal and nonfatal)	3,110 Stroke
23								
24	Cassidy, 2016 <sup>(55)</sup>	Health Professionals Follow-Up Study, US	24y	Men in health professions	32-81	M 43,880	MI (fatal and nonfatal; nonfatal; fatal)	4,046 MI
25	Dower, 2016 <sup>(56)</sup>	Zutphen Elderly Study, Netherlands	R 25	Residents of Zutphen	65-84	M 744	CVD (fatal); CHD (fatal); Stroke (fatal)	148 CHD; 72 Stroke; 329 CVD
26								
27	Goetz, 2016 (CHD) <sup>(57)</sup>	Reasons for Geographic And Racial Differences in Stroke study, US	6.0y (median)	Population-based	45+	MF 16,678	CHD (fatal and nonfatal)	589 CHD
28	Goetz, 2016 (Stroke) <sup>(58)</sup>	Reasons for Geographic And Racial Differences in Stroke study, US	6.0y (median)	Population-based	45+	MF 20,024	Stroke (fatal and nonfatal)	524 Stroke
29								
30	Nagata, 2017 <sup>(59)</sup>	Takayama Study, Japan	16y	Residents of Takayama City	35+	MF 29,079	CVD (fatal)	1,678 CVD
31	Adriouch, 2018 <sup>(60)</sup>	NutriNet-Sante, France	Me 4.9	Volunteers from the NutriNet-Santé study	18+	MF 84,158	CVD (fatal and nonfatal); CHD (fatal and nonfatal); Stroke (fatal and nonfatal)	309 CHD; 293 Stroke; 602 CVD
32								
33	Bondonno, 2019 <sup>(61)</sup>	Danish Diet, Cancer, and Health Study, Denmark	23y, 19.4y (median)	Residents of Copenhagen and Aarhus	50-65	MF 56,048	CVD (fatal)	3,981 CVD
34	Dalgaard, 2019 <sup>(62)</sup>	Danish Diet, Cancer, and Health Study, Denmark	23y, 21y (median)	Residents of Copenhagen and Aarhus	50-65	MF 53,552	CVD (nonfatal)	8,773 CVD
35								
36	Mendonca, 2019 <sup>(63)</sup>	Seguimiento Universidad De Navarra Study, Spain	10.1y	University graduates	20-89	MF 17,065	CVD (fatal and nonfatal)	113 CVD
37	Abbreviations: CHD (coronary heart disease); CVD (cardiovascular disease); F (female); M (male); MI (myocardial infarction); RR (relative risk).							
38								
39								
40								
41								
42								
43								
44								
45								
46								

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

Table 2. Summary relative risks for the highest *versus* the lowest category of individual classes of flavonoids and lignan intake and risk of cardiovascular disease, coronary heart disease and stroke.

Polyphenol class	CHD				Stroke				CVD			
	Datasets (studies)	RR (95% CI)	I <sup>2</sup>	P <sub>heterogeneity</sub>	Datasets (studies)	RR (95% CI)	I <sup>2</sup>	P <sub>heterogeneity</sub>	Datasets (studies)	RR (95% CI)	I <sup>2</sup>	P <sub>heterogeneity</sub>
Flavonoids	3 (3)	0.91 (0.80, 1.05)	0.00	0.782	4 (4)	0.91 (0.78, 1.06)	19.93	0.290	9 (8)	0.81 (0.71, 0.91)	62.25	0.007
Flavonols and flavones	8 (7)	0.86 (0.77, 0.97)	34.52	0.153	4 (4)	0.75 (0.55, 1.03)	66.16	0.031	1 (1)	0.88 (0.68, 1.14)	0.00	1.000
Flavonols	7 (7)	0.90 (0.80, 1.01)	0.00	0.696	5 (5)	0.90 (0.72, 1.13)	65.18	0.022	8 (7)	0.85 (0.79, 0.91)	28.99	0.197
<i>Quercetin</i>	8 (7)	0.87 (0.76, 1.00)	31.68	0.175	2 (2)	0.85 (0.70, 1.03)	0.00	0.694	1 (1)	0.96 (0.74, 1.25)	0.00	1.000
<i>Myricetin</i>	4 (4)	1.07 (0.95, 1.20)	0.00	0.576	2 (2)	1.00 (0.83, 1.21)	0.00	0.545	1 (1)	0.93 (0.73, 1.19)	0.00	1.000
<i>Kaempferol</i>	5 (5)	0.90 (0.81, 1.01)	0.00	0.623	2 (2)	0.72 (0.59, 0.88)	0.00	0.467	1 (1)	0.95 (0.75, 1.21)	0.00	1.000
Flavanones	5 (5)	0.96 (0.84, 1.09)	49.99	0.092	5 (5)	0.86 (0.77, 0.96)	0.00	0.697	8 (7)	0.88 (0.79, 0.98)	63.38	0.008
Flavones	4 (4)	0.99 (0.87, 1.13)	0.00	0.824	5 (5)	0.98 (0.88, 1.09)	0.00	0.773	8 (7)	0.91 (0.82, 1.01)	68.90	0.002
Flavan-3-ols	6 (5)	0.93 (0.86, 1.01)	0.00	0.485	7 (6)	0.95 (0.87, 1.05)	0.00	0.710	9 (7)	0.85 (0.76, 0.95)	67.99	0.002
Catechins	3 (3)	0.81 (0.68, 0.97)	0.00	0.808	2 (2)	0.70 (0.55, 0.88)	0.77	0.315	2 (2)	0.75 (0.63, 0.89)	0.00	0.780
Proanthocyanins	3 (3)	0.79 (0.65, 0.97)	49.97	0.136	4 (4)	0.97 (0.86, 1.08)	0.00	0.825	5 (4)	0.83 (0.73, 0.95)	54.20	0.068
Anthocyanins	4 (4)	0.79 (0.64, 0.98)	66.19	0.031	4 (4)	0.85 (0.69, 1.05)	50.85	0.107	7 (6)	0.82 (0.70, 0.96)	75.09	0.001
Isoflavones	5 (4)	0.99 (0.80, 1.23)	51.65	0.082	5 (4)	0.92 (0.69, 1.21)	84.51	<0.001	6 (5)	0.87 (0.72, 1.04)	75.04	0.001
Lignans	2 (2)	0.82 (0.65, 1.01)	0.00	0.369	2 (2)	0.92 (0.71, 1.19)	0.00	0.601	4 (4)	0.82 (0.65, 1.04)	40.32	0.170

Abbreviations: CHD (coronary heart disease); CVD (cardiovascular disease); RR (relative risk).

Table 3. Dose-response meta-analysis for total flavonoid intake and risk of cardiovascular disease, coronary heart disease and stroke.

Outcome	Datasets (studies)	Flavonoids mg/d, RR (95% CI)						$I^2$ [%]	$P_{heterog}$	$P_{nonlinearity}$
		0	100	200	300	400	500			
<b>CHD risk</b>	2 (2)	1 (ref.)	0.89 (0.80, 1.00)	0.80 (0.64, 1.00)	0.74 (0.56, 0.99)	0.72 (0.52, 0.99)	0.72 (0.53, 1.00)	1	0.501	0.064
<b>CHD fatal</b>	1 (1)	1 (ref.)	0.90 (0.81, 1.00)	0.81 (0.66, 1.00)	0.77 (0.59, 1.00)	0.77 (0.59, 1.02)	0.81 (0.63, 1.05)	NA	NA	0.041
<b>CHD incidence/mortality</b>	3 (3)	1 (ref.)	0.90 (0.84, 0.97)	0.82 (0.70, 0.95)	0.77 (0.63, 0.94)	0.75 (0.61, 0.94)	0.77 (0.62, 0.96)	1	0.483	0.011
<b>Stroke risk</b>	3 (3)	1 (ref.)	0.91 (0.82, 1.01)	0.84 (0.69, 1.02)	0.80 (0.62, 1.03)	0.78 (0.57, 1.06)	0.76 (0.53, 1.10)	1	0.406	0.233
<b>Stroke fatal</b>	1 (1)	1 (ref.)	0.86 (0.68, 1.09)	0.76 (0.50, 1.17)	0.73 (0.44, 1.21)	0.74 (0.45, 1.21)	0.77 (0.49, 1.21)	NA	NA	0.237
<b>Stroke incidence/mortality</b>	4 (4)	1 (ref.)	0.91 (0.83, 0.99)	0.84 (0.71, 0.99)	0.80 (0.65, 0.99)	0.79 (0.63, 1.00)	0.80 (0.62, 1.03)	1	0.649	0.076
<b>Stroke, ischemic</b>	3 (3)	1 (ref.)	0.82 (0.73, 0.93)	0.71 (0.57, 0.88)	0.67 (0.52, 0.86)	0.67 (0.52, 0.86)	0.68 (0.53, 0.87)	1	0.818	0.009
<b>CVD risk</b>	4 (4)	1 (ref.)	0.87 (0.77, 1.00)	0.77 (0.59, 1.00)	0.68 (0.46, 1.00)	0.62 (0.37, 1.01)	0.57 (0.31, 1.03)	47.5	0.076	0.013
<b>CVD fatal</b>	7 (6)	1 (ref.)	0.93 (0.90, 0.97)	0.87 (0.80, 0.94)	0.82 (0.73, 0.92)	0.79 (0.67, 0.92)	0.77 (0.63, 0.94)	47.8	0.028	0.04
<b>CVD incidence/mortality</b>	9 (8)	1 (ref.)	0.93 (0.90, 0.96)	0.86 (0.81, 0.92)	0.81 (0.73, 0.89)	0.76 (0.67, 0.87)	0.73 (0.62, 0.86)	51.8	0.007	0.082

Abbreviations: CHD (coronary heart disease); CVD (cardiovascular disease); RR (relative risk).



Table 4. Subgroup analyses by potential confounding factors for the association between the highest *versus* the lowest intake of total flavonoids and cardiovascular disease risk.

Subgroups	Datasets (studies)	RR (95% CI)	I <sup>2</sup>	P <sub>heterogeneity</sub>
<b>CVD incidence/mortality</b>				
Incidence	5 (4)	0.65 (0.48, 0.88)	73.89	0.004
Mortality	7 (6)	0.87 (0.77, 0.99)	61.73	0.016
<b>Sex</b>				
Men	2 (2)	0.94 (0.65, 1.36)	53.36	0.143
Women	3 (3)	0.75 (0.56, 1.02)	80.07	0.007
<b>Location</b>				
Europe	5 (5)	0.77 (0.59, 1.00)	62.77	0.03
USA	3 (2)	0.87 (0.79, 0.95)	00.00	0.403
<b>Follow-up, y</b>				
<10	4 (3)	0.74 (0.59, 0.92)	60.59	0.055
≥10	5 (5)	0.85 (0.72, 0.99)	62.34	0.031
<b>Sample size</b>				
<10,000	4 (4)	0.65 (0.41, 1.04)	72.27	0.013
≥10,000	5 (4)	0.87 (0.82, 0.93)	15.63	0.315
<b>Study quality</b>				
high*	6 (5)	0.86 (0.78, 0.93)	22.68	0.263
moderate**	3 (3)	0.60 (0.36, 1.03)	86.14	0.001
<b>Adjusted for energy intake</b>				
Yes	6 (5)	0.85 (0.76, 0.96)	26.22	0.238
No	3 (3)	0.60 (0.36, 0.99)	86.08	0.001
<b>Adjusted for diabetic status</b>				
Yes	4 (4)	0.86 (0.65, 1.13)	45.05	0.141
No	5 (4)	0.76 (0.65, 0.90)	73.62	0.004
<b>Adjusted for BMI</b>				
Yes	7 (6)	0.81 (0.71, 0.93)	47.64	0.075
No	2 (2)	0.56 (0.21, 1.53)	88.77	0.003
<b>Adjusted for other dietary factors</b>				
Yes	5 (5)	0.77 (0.59, 1.00)	62.77	0.03
No	4 (3)	0.80 (0.67, 0.97)	70.47	0.017

Abbreviations: CVD (cardiovascular disease); RR (relative risk).




Figure 1. Flow chart of study selection process.

497x528mm (72 x 72 DPI)




Figure 2. Summary relative risks for the highest versus the lowest category of total flavonoid intake and risk of cardiovascular disease, coronary heart disease and stroke.

177x177mm (350 x 350 DPI)





Figure 3

457x177mm (300 x 300 DPI)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 This dose-response meta-analysis investigates the effect of dietary flavonoid intake toward risk of  
4 cardiovascular diseases, coronary heart diseases and stroke in prospective cohort studies. The  
5  
6 results of this study show that diet rich in flavonoids may reduce the risk of cardiovascular diseases.  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review